Larimar Therapeutics, Inc.
LRMR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001374690
In the last 90 days, Larimar Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 163 institutions reported holding it in 13F filings for Q2 2026, worth $291.4M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Larimar Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 65 | 65 | 0 |
| Shares | 39.0M | 38.7M | −281.8K (−0.7%) |
| Value | $120.2M | $153.0M | +$32.8M (+27.3%) |
New holders (8)
Institutions that held Larimar Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 682,868 | $2.70M | 1.00% |
| Boothbay Fund Management, LLC | 147,203 | $581.5K | 0.02% |
| Pale Fire Capital SE | 12,040 | $47.6K | 0.00% |
| American Century Companies Inc | 11,646 | $46.0K | 0.00% |
| Voya Investment Management LLC | 11,473 | $45.3K | 0.00% |
| SG Americas Securities, LLC | 11,120 | $44.0K | 0.00% |
| Advisor Group Holdings, Inc. | 1,000 | $3.95K | 0.00% |
| CWM, LLC | 86 | $0 | 0.00% |
Sold out (8)
Institutions that held Larimar Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Deutsche Bank AG | 255,593 | $800.0K |
| Millennium Management LLC | 114,740 | $359.1K |
| Jane Street Group, LLC | 19,565 | $61.2K |
| Prelude Capital Management, LLC | 19,013 | $59.5K |
| Susquehanna International Group, LLP | 12,818 | $40.1K |
| Jump Financial, LLC | 11,700 | $36.6K |
| Group One Trading, L.P. | 500 | $1.56K |
| Disciplined Investments, LLC | 116 | $363 |